2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 951

IFN-Gamma Production in Lyme Arthritis Synovial Tissue Promotes Differentiation of Fibroblast-like Synoviocytes into Inflammatory Effector Cells
Abstract Number: 2112

IFN-Gene Expression Is Elevated in Subacute Cutaneous Lupus Erythematous and DLE and Decreases with Treatment in DLE
Abstract Number: 2111

Ifnβ Affects Osteogenesis-Adipogenesis Axis in SLE Bone Marrow
Abstract Number: 168

IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Abstract Number: 855

IgG Antiphospholipid Antibodies, -a Common but Neglected Finding in Patients with Myocardial Infarction
Abstract Number: 1775

IgG4-Related Disease, Clinical Series on Chilean Patients
Abstract Number: 238

IL Inhibitors Therapy in Rheumatic Diseases and the Risk of Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials
Abstract Number: 1985

IL-1β Inhibits the Expression of Dickkopf-1, an Antagonist of the Wnt-β-Catenin Signaling Pathway: A Possible Role of Inflammasome in Dysregulation of Endochondral Ossification
Abstract Number: 2795

IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody Formation in Lupus
Abstract Number: 879

IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis
Abstract Number: 985

IL-6 and TNF-a Cooperate to Modulate Cell Cycle of RA-FLS Via Cyclin Dependent Kinase 6
Abstract Number: 1685

IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients
Abstract Number: 317

Imaging Biomarker Based Patient Stratification: Initial Data and Validation in Four Most Common Knee Arthritic Diseases
Abstract Number: 362

Immune Check Point Inhibitors, Auto-Antibodies, and Immune Adverse Reactions
Abstract Number: 2976

Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].